Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212
Status:
Completed
Trial end date:
2018-10-17
Target enrollment:
Participant gender:
Summary
This is an open-label safety extension study to assess the safety and tolerability of once
daily dosing of 590 mg Liposomal Amikacin for Inhalation (LAI) added to a multi-drug regimen
in participants with nontuberculous mycobacterial (NTM) lung infections due to Mycobacterium
avium complex (MAC) who were refractory to therapy and failed to convert in Study INS-212
(NCT02344004).